Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
about
Imatinib in chronic myeloid leukemia: an overviewTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Treatment of chronic myeloid leukemia when imatinib fails.The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.A review of the European LeukemiaNet recommendations for the management of CML.A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.CML--Where do we stand in 2015?Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
P2860
Q26865086-D4FC7CCD-1E63-4A96-8D19-A8C50BB36BEAQ30242015-3A590388-1BAE-4907-AAE1-890E6BECBB46Q36708942-DAB02B51-A634-4CB4-8129-A04A4F78059AQ37026032-5EB310C9-7BA2-4780-B6B6-7830C48959F4Q37827875-BC90292F-BEA6-4387-953C-7727290ADC98Q37896606-D6A721BE-2754-422C-9855-B79DC3A6DFF8Q38199143-51586A2A-BF38-448E-BB5E-471471C6E0E2Q38392676-00A303A8-A974-4E3A-97A7-BB26C3F90E72Q39259447-80B55BE3-A42A-4112-BE51-FAE8D904B371Q39637488-57B9F3D8-46DF-4C23-998E-4E061858DEDAQ39924810-63F328BA-213D-4AEF-8827-D3DF785E75FFQ40821920-6CA5D030-A8AB-4FAC-BBB8-FFF93E8FD7D6Q41293762-86BBD0AA-5456-40AE-87EA-D8E72B00908EQ42117946-B23ECF77-3D49-42E6-8098-DA2A3C55FBDFQ48778777-0333E603-07E4-41BA-9EB4-E0481481BA5CQ50586934-8663025E-7AEF-4AED-AA69-B71F7F7B024DQ50916805-E7FD77CE-2050-4A13-869A-27EC7C0ACA7BQ51821011-AB27B3EA-FCEC-4126-9435-78AEE36568C4Q54281648-8093A032-5B6D-4409-8EB1-BEE6CB23F76AQ54333450-E3155D57-7C5B-4371-8FD7-09A3F790E179Q54596369-8428B2DB-1A33-4BD4-A60F-7218F203D3D5
P2860
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Early intervention during imat ...... of the Spanish PETHEMA group.
@ast
Early intervention during imat ...... of the Spanish PETHEMA group.
@en
type
label
Early intervention during imat ...... of the Spanish PETHEMA group.
@ast
Early intervention during imat ...... of the Spanish PETHEMA group.
@en
prefLabel
Early intervention during imat ...... of the Spanish PETHEMA group.
@ast
Early intervention during imat ...... of the Spanish PETHEMA group.
@en
P2093
P2860
P1433
P1476
Early intervention during imat ...... of the Spanish PETHEMA group.
@en
P2093
Anna Sureda
Arturo Pereira
Cristina Pérez-López
Fermín Jonte
Francisco Cervantes
Gloria Pérez-Rus
Jesús Martínez
José B Nieto
José Román-Gómez
Juan-Carlos Hernández-Boluda
P2860
P304
P356
10.3324/HAEMATOL.2009.021154
P577
2010-03-10T00:00:00Z